Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) EBT (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed EBT for 16 consecutive years, with -$1.1 million as the latest value for Q3 2025.

  • On a quarterly basis, EBT rose 74.75% to -$1.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$67.0 million, a 401.92% decrease, with the full-year FY2024 number at -$11.7 million, down 356.38% from a year prior.
  • EBT was -$1.1 million for Q3 2025 at Harvard Bioscience, up from -$2.3 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $3.4 million in Q2 2022 to a low of -$50.8 million in Q1 2025.
  • A 5-year average of -$4.7 million and a median of -$1.1 million in 2023 define the central range for EBT.
  • Biggest YoY gain for EBT was 641.3% in 2022; the steepest drop was 10522.22% in 2022.
  • Harvard Bioscience's EBT stood at $1.1 million in 2021, then plummeted by 178.87% to -$892000.0 in 2022, then decreased by 23.65% to -$1.1 million in 2023, then tumbled by 1066.36% to -$12.9 million in 2024, then skyrocketed by 91.19% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's EBT are -$1.1 million (Q3 2025), -$2.3 million (Q2 2025), and -$50.8 million (Q1 2025).